Yu Wenshu, Wu Na
Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China.
Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China; Clinical Skill Practice Teaching Center, Shengjing Hospital of China Medical University, Shenyang, China.
Ann Palliat Med. 2020 Nov;9(6):4359-4370. doi: 10.21037/apm-20-1828. Epub 2020 Nov 10.
Primary hypothyroidism with pituitary hyperplasia is a rare entity. It is characterized by hypogonadotropic hypogonadism and growth hormone (GH) deficiency. Despite advances in imaging, it is still not possible to clearly distinguish pituitary hyperplasia from pituitary tumors. We describe a case of primary hypothyroidism associated with pituitary hyperplasia. We reviewed 18 case reports of children or adolescents with short stature or hypogonadotropic hypogonadism from 2001 to 2019. In the present report, we studied a 15-year-old adolescent male whose first diagnosis was low gonadotropin development and growth retardation. Imaging examination revealed nodular signals in the saddle area of the pituitary gland, and endocrine function tests showed primary hypothyroidism. Levothyroxine tablets were taken as replacement therapy. A literature search found that 17 studies reported delayed bone age and growth retardation, but only 6 studies measured GH; 5 studies showed a decrease in GH. To distinguish primary hypothyroidism with subsequent pituitary hyperplasia from pituitary tumors, the definitive diagnosis should be based on clinical symptoms, endocrine examination, and prognosis following medication. For patients with hypothyroidism, thyroid hormone replacement therapy can result in a satisfactory prognosis, as well as improvements in clinical symptoms and serologic values. The pituitary function of those with pituitary hyperplasia can be slowly restored after negative feedback inhibition is rebalanced. However, patients with pituitary tumors should undergo surgery.
原发性甲状腺功能减退伴垂体增生是一种罕见的病症。其特征为低促性腺激素性性腺功能减退和生长激素(GH)缺乏。尽管影像学取得了进展,但仍无法清晰区分垂体增生与垂体肿瘤。我们描述了一例与垂体增生相关的原发性甲状腺功能减退病例。我们回顾了2001年至2019年18例身材矮小或低促性腺激素性性腺功能减退儿童或青少年的病例报告。在本报告中,我们研究了一名15岁的青少年男性,其最初诊断为促性腺激素发育低下和生长发育迟缓。影像学检查显示垂体鞍区有结节状信号,内分泌功能检查显示原发性甲状腺功能减退。给予左甲状腺素片进行替代治疗。文献检索发现,17项研究报告了骨龄延迟和生长发育迟缓,但只有6项研究检测了GH;5项研究显示GH降低。为了将原发性甲状腺功能减退伴随后的垂体增生与垂体肿瘤区分开来,明确诊断应基于临床症状、内分泌检查以及用药后的预后情况。对于甲状腺功能减退患者,甲状腺激素替代治疗可带来满意的预后,临床症状和血清学指标也会有所改善。垂体增生患者在负反馈抑制重新平衡后,垂体功能可缓慢恢复。然而,垂体肿瘤患者应接受手术治疗。